Upcoming Events

Come join us on Monday, August 26 as we hear from David Esposito, CEO of ONL Therapeutics. ONL Therapeutics Inc. produces the product ONL 1204, which is intended to protect the vision of patients with retinal disease.  The story will be about the unmet need of patient’s with retinal disease and a physician’s frustration over being unable to answer the question from patients – “what else can we do?” ONL1204 offers a potential answer to this troubling question. Rotarians will receive…